Relapse Clinical Trial
Official title:
Comparative Evaluation of 3 Dimensional Changes of Dentition in Post Orthodontic Patients With Immediate vs Delayed (Post 3 Days) Retainer Delivery-A Randomized Control Trial"
Maintaining teeth in their corrected position after orthodontic treatment is one of the most challenging part of orthodontic treatment and hence a period of stabilization termed as retention is provided after orthodontic treatment. Retention is one of the most important phase of orthodontic treatment that attempts to keep teeth in the corrected positions after treatment with orthodontic braces. Following literature search there is no scientific evidence for the timing of retainer delivery.The present study is designed to know if post orthodontic tooth movement vary with different time of retainer delivery and since there is unusual delay after debonding as the retainer is fabricated at the laboratory. Such a study will help us to find out within which time period the retainer should be delivered
Status | Recruiting |
Enrollment | 40 |
Est. completion date | April 25, 2024 |
Est. primary completion date | December 25, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 45 Years |
Eligibility | Inclusion Criteria: - Adult orthodontic patients treated with 022*028 MBT appliance with following sequence of wires- 014, 016, 16*22, 17*25, 19*25 NiTi followed by 19*25 SS. - Treatment duration of 24-36 months with Optimal functional occlusion at end of treatment (PAR score >70%). - Class I bimax and Class II div I with pre-treatment Little's irregularity index <6mm in both upper and lower arch. - Nonsurgical and non-orthopedic patients. - Non syndromic patients and no impaction of teeth except third molars. - No previous orthodontic treatment. - Optimal periodontal condition and Good oral hygiene. - Good compliance regarding retainer wear (Cases who never missed more than 2 consecutive appointment and who reported with less no of breakages). Exclusion Criteria: - Subjects with incomplete orthodontic treatment. - TMJ disorder patients. - Any systemic disease affecting bone and general growth. - Patients with incomplete records. - Patient who fail to follow up or undergo complete treatment. - Patient with learning difficulties |
Country | Name | City | State |
---|---|---|---|
India | Post Graduate Institute of Dental Sciences | Rohtak | Haryana |
Lead Sponsor | Collaborator |
---|---|
Postgraduate Institute of Dental Sciences Rohtak |
India,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | overjet | sagittal distance between upper and lower incisors | T0-baseline on the day of debonding | |
Primary | overjet | sagittal distance between upper and lower incisors | T1- 3 days after debonding | |
Primary | overjet | sagittal distance between upper and lower incisors | T2- 1 month after debonding | |
Primary | overjet | sagittal distance between upper and lower incisors | T3- 3 months after debonding | |
Primary | overjet | sagittal distance between upper and lower incisors | T4- 6 months after debonding | |
Primary | contact point displacement | displacement of contact points in anterior teeth | T0-baseline on the day of debonding | |
Primary | contact point displacement | displacement of contact points in anterior teeth | T1- 3 days after debonding | |
Primary | contact point displacement | displacement of contact points in anterior teeth | T2- 1 month after debonding | |
Primary | contact point displacement | displacement of contact points in anterior teeth | T3- 3 months after debonding | |
Primary | contact point displacement | displacement of contact points in anterior teeth | T4- 6 months after debonding | |
Primary | Overbite | vertical overlap of upper and lower incisors | T0- Baseline on the day of debonding | |
Primary | Overbite | vertical overlap of upper and lower incisors | T1- 3 days after debonding | |
Primary | Overbite | vertical overlap of upper and lower incisors | T2- 1 month after debonding | |
Primary | Overbite | vertical overlap of upper and lower incisors | T3- 3 months after debonding | |
Primary | Overbite | vertical overlap of upper and lower incisors | T4- 6 months after debonding | |
Primary | Intermolar width | transverse distance between the first molars | T0-baseline on the day of debonding | |
Primary | Intermolar width | transverse distance between the first molars | T1- 3 days after debonding | |
Primary | Intermolar width | transverse distance between the first molars | T2- 1 month after debonding | |
Primary | Intermolar width | transverse distance between the first molars | T3- 3 months after debonding | |
Primary | Intermolar width | transverse distance between the first molars | T4- 6 months after debonding | |
Primary | Intercanine width | transverse distance between canine | T0-baseline on the day of debonding | |
Primary | Intercanine width | transverse distance between canine | T1- 3 days after debonding | |
Primary | Intercanine width | transverse distance between canine | T2- 1 month after debonding | |
Primary | Intercanine width | transverse distance between canine | T3- 3 months after debonding | |
Primary | Intercanine width | transverse distance between canine | T4- 6 months after debonding |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT00306813 -
Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1/Phase 2 | |
Completed |
NCT01956695 -
Efficacy of Lenalidomide With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma
|
Phase 2 | |
Not yet recruiting |
NCT05926167 -
Observational Trial Evaluating Elevated Factor VIII Related Labs as a Biomarker for Incomplete Relapse Recovery
|
||
Recruiting |
NCT03710512 -
Evaluation of Early Relapse After Mandibular Lengthening Surgery
|
||
Recruiting |
NCT04921540 -
Ingrown Toenails : Surgery Only Versus Surgery + Chemical Cauterization With TCA
|
N/A | |
Not yet recruiting |
NCT03830827 -
MBRP + Vortioxetine VS MBRP on Preventing Relapse in Chronic MA Users
|
Phase 4 | |
Completed |
NCT05250765 -
Comparison of Efficiency and Effectiveness of Two Types of Bonded Orthodontic Retainers: an RCT.
|
N/A | |
Completed |
NCT05915273 -
Relapse and Failure Rates Between CAD/CAM and Conventional Fixed Retainers
|
N/A | |
Active, not recruiting |
NCT04389879 -
CAD/CAM Fixed Retainers vs. Conventional Multistranded Fixed Retainers in Orthodontic Patients. Comparison of Stability, Retainer Failure Rate, Adverse Effects, Cost-effectiveness, and Patient Satisfaction. A Randomized Controlled Clinical Trial
|
N/A | |
Recruiting |
NCT06417359 -
Comparison of Mesh Fixation and Non-Fixation in eTEP
|
N/A | |
Recruiting |
NCT06417346 -
Comparison of Laparoscopic and Open Inguinal Hernia Repair in Elderly Patients
|
N/A | |
Completed |
NCT02145403 -
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT01481701 -
A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma
|
Phase 2 | |
Recruiting |
NCT01941394 -
Mesenchymal Stem Cells Infusion for aGVHD Prophylaxis Transplantation
|
Phase 2 | |
Recruiting |
NCT04723901 -
Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04994626 -
Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies
|
Phase 2 | |
Recruiting |
NCT06292364 -
Comparison of Retention Characteristics of Immediate vs Delayed Retainer Delivery Using 3D Digital Model Analysis
|
N/A | |
Enrolling by invitation |
NCT05591703 -
Clinical Outcomes Following Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention: A Long-term Follow-up Study
|
||
Active, not recruiting |
NCT00299923 -
Study for Patients With Chronic HCV (GT 1 or 3) Who Relapsed to Previous (Peg)Interferon/ Ribavirin Combination Therapy
|
Phase 3 |